IP Library Granted Patent US 8,946,303
Granted Patent B2
US 8,946,303 · App. 10/541,020 · Granted Feb 3, 2015

Fatigue reducing agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,303
App. No.
10/541,020
Granted
Feb 3, 2015
Kind
B2
Abstract

To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe so that long-term administration is possible. A composition containing reduced coenzyme Q was found to be effective for preventing and reducing fatigue, including muscle fatigue. Since the fatigue reducing effect of the composition of the present invention is seen not only in young rats but also more pronounced in aged rats, the present invention can provide the fatigue reducing agent which is very useful, especially, for middle-aged and older persons as well as for young people.

Claims (8)

1. A method for reducing fatigue in animals in the state of fatigue, wherein the animals are middle aged or older persons and wherein the fatigue is physical exhaustion, which comprises administering, to said animals, a fatigue reducing agent in a therapeutically effective amount comprising, as an active ingredient

reduced coenzyme Q represented by the following formula (1) (wherein n represents 10)

and oxidized coenzyme Q represented by the following formula (2) (wherein n represents 10)

wherein a ratio of reduced coenzyme Q to total coenzyme Q is not less than 99% by weight, or

reduced coenzyme Q represented by the above formula (1) (wherein n represents 10) in an amount of 100% based on total coenzyme Q.

2. The method according to claim 1 , wherein the fatigue reducing agent is administered orally.

3. The method according to claim 1 , wherein the active ingredient is reduced coenzyme Q and oxidized coenzyme Q and the ratio of reduced coenzyme Q to total coenzyme Q is 99% by weight.

4. The method according to claim 1 , wherein the active ingredient is reduced coenzyme Q and oxidized coenzyme Q and the ratio of reduced coenzyme Q to total coenzyme Q is 99 to 99.5% by weight.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 12, 2013
From: KANEKA CORPORATION
To: KANEKA CORPORATION
Reel/Frame 031207/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2005
From: FUJII, KENJI; KAWABE, TAIZO; HOSOE, KAZUNORI; HIDAKA, TAKAYOSHI
To: KANEKA CORPORATION
Reel/Frame 017445/0572 →